The Transparency Gap: Decoding ‘Made in USA’ Claims for Experimental Compounds

Man in a blazer and glasses sits at a desk by a window, reading a document labeled MADE IN USA.

Table of Contents

The Illusion of Domestic Origin in Cellular Health

An American flag on a supplement label tells you where the capsule was filled — not where the active compound was synthesized.

Walk through any longevity or experimental compound retailer's website online and the marketing pattern becomes predictable: bold red-white-and-blue imagery, "Made in USA" prominently displayed, language designed to signal domestic quality and oversight. The visual cues are deliberate. Yet the raw materials inside those capsules — the amino acids, peptide precursors, and bioactive compounds — frequently originate thousands of miles away. According to the U.S.-China Economic and Security Review Commission, a significant portion of the global supply of key vitamins and raw ingredients, including Vitamin C and various amino acids, originates in China. That figure reframes what domestic production actually means for the cellular health industry.

"Made in USA" is arguably the most misunderstood claim in the experimental compound space — not because it is always false, but because it is almost never defined clearly enough to be meaningful. The Federal Trade Commission requires that products claiming unqualified domestic origin be "all or virtually all" made in the United States. What counts as "made," however, is where the transparency gap begins. For finished supplements and experimental peptides, the critical distinction is between chemical synthesis — the actual creation of the active compound at a molecular level — and downstream processing steps like encapsulation, filling, and packaging. Most domestic operations perform the latter, not the former.

This is the core issue that evidence-aware researchers need to understand: the industry often shifts from domestic manufacturing to domestic finishing. Raw bulk compound — synthesized offshore — arrives at a U.S. facility, where it is measured, encapsulated, labeled, and shipped. The facility may hold legitimate certifications and maintain clean-room standards. None of that changes where the active ingredient was created or what quality controls governed that original synthesis step.

Understanding this gap requires familiarity with the broader supply structure — specifically the distinction between private label vs contract manufacturing, two models that look similar on a product label but represent meaningfully different levels of formulation control and vendor accountability. Before evaluating any compound's origin claims, it is worth defining exactly what each stage of production actually means.

Key Terminology: Defining the Stages of Production

Understanding where a compound is made requires separating four distinct production stages — each of which can occur in a different country, under a different standard, and with a different legal disclosure requirement.

The FTC Made in USA standard applies to the product as a whole, but supplement manufacturing is not a single event. It is a chain. Each link in that chain carries its own origin story, and marketers have become skilled at highlighting the most favorable link while obscuring the rest. Before evaluating any "Made in USA" claim on an experimental compound, a reader needs a working vocabulary for what actually happens between raw chemical synthesis and the finished bottle on a shelf.

Chemical Synthesis (Manufacturing)
The stage at which the active compound is chemically constructed from precursor materials — the origin point that determines where the compound itself was actually created, regardless of what happens downstream.
Bulk API (Active Pharmaceutical Ingredient)
The raw, unformulated form of a synthesized compound, typically produced at a dedicated chemical facility and then shipped to a separate formulation or filling site.
Filling
The process of placing a bulk finished compound into its final delivery format — capsules, vials, or sachets — which, as the FTC’s enforcement guidance notes, can occur domestically even when every ingredient was imported.
Packaging
The final production stage covering bottling, labeling, and lot-number assignment — a domestic step that contributes nothing to the origin of the active compound inside.
Private Labeling
A commercial arrangement in which a brand purchases an existing formula from a contract manufacturer and applies its own label — meaning the brand may have no involvement in synthesis, formulation, or quality verification whatsoever.

A product labeled "filled in a USA-certified facility" tells the reader about geography, not synthesis. The compound inside that capsule may have been synthesized overseas, shipped as bulk API, and handed off to a domestic filler — a workflow that is entirely legal but frequently misrepresented through selective labeling language.

This distinction matters most for experimental compounds like mitochondria-targeting peptides, where synthesis complexity and purity verification are central to research validity. Understanding how peptide origin affects compound integrity is foundational to reading sourcing claims with appropriate skepticism.

The production stage vocabulary above sets the groundwork for a more pressing question: what legal threshold must a company actually meet before printing "Made in USA" on a label — and what enforcement mechanisms exist when that threshold is not met?

The FTC 'Made in USA' Standard: Unqualified vs. Qualified Claims

The legal threshold for a domestic origin claim is specific — and most supplement vendors quietly operate below it.

The Federal Trade Commission's Made in USA Labeling Rule, codified under 16 CFR part 323, establishes two distinct categories of domestic origin claims: unqualified and qualified. Understanding the difference is not an academic exercise. For anyone evaluating vendor transparency around experimental compounds, this distinction directly determines whether a label is accurate or misleading.

Unqualified claims: The 'all or virtually all' threshold

An unqualified 'Made in USA' claim carries the highest legal burden. According to the FTC, to make such a claim, the product must be "all or virtually all" made in the United States. This means:

  • All significant parts, processing, and labor must originate domestically
  • Any foreign content must be negligible — both in terms of cost and the product's total manufacturing
  • The final assembly or processing must occur on U.S. soil

In the context of experimental peptides and nootropics, this standard is nearly impossible to meet. Most active pharmaceutical-grade raw materials — including synthesized peptides — originate in overseas facilities, primarily in Asia. A capsule filled in a U.S. facility still contains foreign-synthesized active ingredients, which disqualifies the product from an unqualified claim.

Qualified claims: The legal workaround for imported inputs

When foreign raw materials are involved, the FTC permits qualified claims — statements that explicitly disclose the foreign content. Examples include "Made in USA with imported ingredients" or "Assembled in USA from global components." These qualifications must be:

  • Clearly visible and proximate to the origin claim
  • Specific enough that a reasonable consumer understands the extent of domestic versus foreign content
  • Not framed to minimize or obscure the foreign input

A common pattern in the supplement industry is to use broad domestic language while burying qualification language in small print — a practice that sits at the edge of deceptive labeling.

Enforcement: Real penalties under the new rule

The 2021 rule formalized civil penalties for violations — up to $51,744 per violation under current FTC enforcement guidelines. An executive order signaling heightened enforcement in 2026 has raised the stakes further.

What the legal framework does not resolve, however, is the practical challenge of identifying where synthesis — not just packaging — actually occurs. That gap between regulatory language and manufacturing reality is precisely where vendor documentation requires the closest scrutiny.

US Manufactured: The Myth of Domestic Synthesis

Most vendors who claim "Manufactured in USA" are describing a blending operation — not a synthesis process.

That distinction matters more than the label suggests. Synthesis is the chemical process by which a molecule is constructed from raw precursors. Blending is the mechanical process of combining pre-made powders — often sourced from overseas manufacturers — into capsules or powders at a domestic facility. These are fundamentally different operations, yet both can appear behind the same "Manufactured in USA" claim.

Blending imported ingredients domestically does not constitute domestic synthesis. According to the FTC's Made in USA standard, unqualified vs. qualified claims hinge on whether the product's components are "all or virtually all" of U.S. origin. A vendor blending Chinese-synthesized peptide powder into capsules at a U.S. facility cannot lawfully make an unqualified domestic origin claim — yet many do. The FTC is explicit: if a supplement is "US Filled" but the raw ingredients are imported, an unqualified "Made in USA" claim is a violation of federal law.

Domestic synthesis of peptides and advanced nootropics is genuinely rare. Full-chain peptide synthesis requires specialized equipment, trained chemists, and regulatory infrastructure that most small supplement vendors do not operate. The majority of peptide active pharmaceutical ingredients — including compounds like BPC-157, TB-500, and related research peptides — are synthesized in China or India, then exported as bulk powder for downstream processing. A Morgan Lewis compliance review notes that many companies underestimate how far upstream the origin analysis must travel.

Synthesis-washing is the practice of using vague manufacturing language to imply domestic synthesis without explicitly claiming it. In vendor documentation, watch for these patterns:

  • "Formulated in USA" — references the blending stage, not synthesis
  • "Manufactured at a USA-certified facility" — describes the building, not the molecular origin
  • "Quality-tested in the USA" — a post-production step unrelated to where the compound was made
  • No Certificate of Analysis origin disclosure — a meaningful gap in transparent sourcing

Evaluating these claims requires reading past the marketing copy and into the actual documentation — a practice the next section extends into the specific mechanics of domestic filling and packaging operations.

US Filled and US Packaged: The 'Bottled in USA' Reality

The distinction between US Manufactured vs US Filled is not semantic — it defines whether any meaningful domestic production occurred at all.

When a vendor receives a shipment of bulk capsules pre-filled overseas, the domestic operation that follows is straightforward: inspect, count, bottle, label, and ship. That sequence qualifies as packaging. It does not qualify as manufacturing. Yet the marketing language applied to the final product frequently suggests otherwise.

The technical process of "filling" describes encapsulating raw or blended powder into a capsule shell — a step that, when performed domestically, can support a manufacturing claim. When that step happens abroad and finished capsules arrive ready for bottling, the domestic contribution shrinks to logistics. As NIST labeling guidance notes, companies importing bulk finished capsules must use specific language — "Packaged in USA" or "Bottled in USA" — rather than broader manufacturing claims.

"Packaged in USA" is, for many vendors, the most accurate claim available — and the one least likely to appear prominently on the label.

What appears instead is often a US flag, a map outline, or a tagline referencing American quality. These visual signals carry no regulatory meaning. The FTC's Made in USA framework governs text claims, not imagery — which means a vendor can display unmistakably patriotic branding while the fine print reads "Packaged in USA" in a secondary font.

The distinction between "Assembled in USA" and "Packaged in USA" carries its own regulatory weight:

  • Assembled in USA — Requires that principal assembly occur domestically and that assembly be a meaningful part of production, not merely affixing a label or placing items in a container
  • Packaged in USA — Describes a purely logistical operation: placing a finished product into its final retail container on US soil
  • Bottled in USA — Functionally equivalent to “Packaged in USA” for liquid or capsule formats; no synthesis or formulation implied
  • Made in USA (qualified) — Requires disclosure of foreign content and limits the scope of the domestic claim

"An unqualified 'Made in USA' claim should only be made when the product is 'all or virtually all' made in the United States." — FTC, Complying with the Made in USA Standard

"Qualified claims — such as 'Made in USA of US and imported parts' — are permissible but must be conspicuous and non-deceptive." — Federal Register, Made in USA Labeling Rule

"Consumers reasonably interpret 'Made in USA' to mean the product was manufactured here — not simply sorted, bottled, or labeled." — BBB National Programs

Understanding where a product is actually produced — versus where it is packaged — is the first filter in any credible compound verification process. The next layer of complexity involves who controls the production relationship itself: whether a vendor owns a formula or simply purchases an existing one.

Private label vs. contract manufacturing: Who owns the quality?

The business model behind a vendor determines how much transparency is structurally possible — and private labeling makes genuine compound verification nearly impossible.

In the peptide and longevity space, two dominant models exist: private labeling and contract manufacturing. Understanding the difference is not a minor technical detail. It directly shapes what a vendor can honestly disclose about sourcing, purity, and CGMP compliance for supplements they sell under their brand.

Private labeling is the simpler model. A vendor purchases a pre-made bulk compound or finished product from a third-party manufacturer, applies their own branding, and sells it. No custom formulation occurs. No production oversight exists on the vendor's side. As American Law Label, Inc. notes, private labeling often obscures the original source of the compound — multiple competing brands may draw from the same undifferentiated bulk supplier while presenting entirely distinct brand identities to consumers. The vendor may not even know the API's country of origin with certainty.

This creates the white label trap: a vendor can claim domestic business operations, list a US address, and invest heavily in professional packaging — all while having zero visibility into where the active compound was synthesized or how it was tested upstream. For experimental compounds like peptides, where no FDA-regulated finished-product standard exists, this opacity is particularly significant. There is no regulatory mechanism forcing a private label vendor to trace the compound back to its synthesis origin.

Contract manufacturing operates differently. Here, a vendor engages a manufacturer to produce a formulation to their specification. The vendor defines the compound, the dose, the excipients, and — ideally — the testing requirements. This model creates at least the structural potential for transparency: the vendor can request certificates of analysis, specify incoming material testing, and document supplier qualification steps. Whether any given vendor actually exercises that oversight varies widely. Contract manufacturing creates the conditions for accountability; it does not guarantee it.

The practical question worth asking any vendor is direct: Are you a private label operation, or do you hold a contract manufacturing agreement with documented quality specifications?

  • Private label vendors typically cannot answer this question with specifics.
  • Contract manufacturers can point to supplier qualification records, batch-level testing data, and formulation documentation.

That documentation trail — or its absence — connects directly to the next layer of quality claims vendors routinely make: GMP certification.

The GMP fallacy: Process vs. purity

GMP certification validates a manufacturing environment — it does not certify the origin, purity, or biological activity of the ingredients processed within it.

This distinction matters enormously for researchers evaluating experimental compounds. A vendor displaying GMP compliance signals that their facility follows documented procedures, maintains records, and operates in a controlled environment. What that certification does not address is what raw materials entered the facility in the first place.

21 CFR Part 111, the FDA's framework governing dietary supplement manufacturing, regulates process controls, personnel hygiene, equipment cleaning protocols, and batch record documentation. It establishes the conditions under which a product is made — not the quality or geographic origin of what goes into it. As the Natural Products Association acknowledges in the context of 21 CFR Part 111: the GMP certification of a facility does not guarantee the purity or origin of the raw ingredients used within that facility.

What GMP does NOT cover — a practical checklist:

  • The country of origin of active pharmaceutical ingredients or peptide raw materials
  • Whether imported bulk powders underwent independent potency or identity testing before use
  • The biological activity or research-grade purity of finished compounds
  • Whether a vendor's supplier audit program is rigorous or merely nominal
  • Contaminant profiles in incoming raw materials from overseas sources

The mechanism that is supposed to bridge this gap is incoming material testing — a GMP sub-requirement mandating that manufacturers verify raw ingredients against established specifications before production begins. In practice, the depth of this testing varies widely. A facility can technically satisfy GMP incoming material requirements with basic identity confirmation while still processing peptide raw materials of uncertain purity sourced from low-oversight suppliers.

This creates the distinction researchers must internalize: a GMP facility and a GMP product are not equivalent claims. A facility can hold a valid GMP certification while producing a compound whose active ingredient arrived as an unverified bulk import. The certificate speaks to the room, not to what was measured inside it.

The logical extension of this analysis is that process compliance alone is insufficient for compound verification. Determining whether a product meets research-grade standards requires interrogating the quality assurance layer that sits upstream of production — specifically, the protocols governing what enters the facility and how consistently those protocols are applied. That is precisely where the next evaluation framework begins.

Quality assurance: The part that ensures consistency

Quality assurance is the system that makes a manufacturing result repeatable — and without it, even a technically pure batch tells you nothing about the next one.

What is the specific role of QA in manufacturing? Current Good Manufacturing Practice (CGMP) is the part of quality assurance that ensures products are consistently produced and controlled to defined quality standards. The distinction matters: QA governs the entire production system, while quality control (QC) addresses product testing at specific checkpoints. A vendor can pass QC on a single batch and still operate without the broader QA infrastructure that makes consistency possible across production runs.

Intended use shapes the applicable QA standard. Peptides sold as research chemicals occupy an ambiguous regulatory space. They are not subject to the same CGMP requirements as pharmaceutical drugs, yet some vendors voluntarily apply pharmaceutical-grade QA frameworks — and others do not. The gap between those two positions is significant. A vendor synthesizing a compound without documented process controls, deviation logs, or validated analytical methods introduces variability that a single certificate of analysis cannot capture. Researchers evaluating experimental compounds need to ask not just "was this batch tested?" but "is the system that produced this batch controlled?"

Verifying QA protocols requires looking past surface-level claims. In practice, researchers can apply the following framework:

  • Request the batch record format — not just the certificate of analysis. A legitimate QA system generates traceable production documentation.
  • Ask about deviation handling — how the vendor documents and resolves out-of-specification events.
  • Confirm analytical method validation — whether the HPLC or mass spectrometry methods used have defined limits of detection and quantitation.
  • Check for third-party audits — internal QA is self-reported; independent audits create an external verification layer.

Internal QA alone is structurally insufficient. A vendor's internal quality team reports to the same organization that has a financial incentive to ship product. Third-party verification — whether through independent laboratory analysis or facility audits — creates the separation necessary for genuine accountability. This is why compound verification frameworks prioritize external evidence over vendor-issued documentation.

The QA picture, however, is only part of what shapes a vendor's transparency posture. Marketing language introduces a separate layer of complexity — one that often obscures the sourcing and manufacturing realities that QA protocols are meant to govern.

Common marketing misconceptions and deception tactics

Brands mislead researchers not through outright lies but through carefully constructed omissions — visual cues, fine-print qualifiers, and conflated certifications that create a false impression of domestic synthesis.

Understanding where these tactics appear is the first step toward reading supply chain claims with genuine research literacy. The five patterns below appear consistently across the experimental compound market.

  1. The "Global Materials" loophole. A product labeled "Made in USA from global materials" discloses foreign sourcing — but the disclosure is typically buried in fine print below a prominent domestic claim. As Reddit discussions among tool and product buyers document, most consumers read the bold claim and miss the qualifier entirely. For peptide researchers, that buried phrase often means the active compound itself was synthesized overseas and only encapsulated or bottled domestically.

  2. Misleading imagery: Flags, eagles, and "Heartland" branding. Visual identity is a powerful signal — and vendors exploit it. According to NIST labeling guidance, marketing misconceptions commonly arise when brands use imagery to imply domestic synthesis when only the final bottling occurred locally. An American flag on a label communicates nothing verifiable about where the active ingredient was synthesized. Visual patriotism is not compound verification.

  3. Conflating "Third-Party Tested" with "US Manufactured." Third-party testing confirms what is in a finished product — it does not confirm where or how the raw material was produced. A compound can be synthesized in an unregulated overseas facility, imported, and then tested by a domestic lab. The COA that results is real, but it reflects the finished product only. The FTC's Made in USA framework draws a clear distinction between manufacturing origin and post-production testing, yet vendors routinely present these as equivalent trust signals.

  4. The "Domestic Lab" distraction. Testing location and synthesis location are separate facts. A vendor can truthfully say a compound was "tested in the USA" while the peptide itself was synthesized abroad. This framing exploits the assumption that laboratory involvement implies domestic production — a gap in research literacy that benefits vendors who lack transparent sourcing.

  5. Selective facility photography. Product pages frequently feature images of clean domestic facilities. Those facilities may handle only final packaging. The synthesis environment — where impurity profiles are actually established — remains invisible.

Recognizing these patterns raises a direct question: how does a researcher actually verify what a vendor claims? The next section provides a structured framework for auditing supply chain documentation — including what to request, what to interpret, and what omissions signal a red flag.

Verification framework: How to audit a vendor's supply chain

Verifying a vendor's supply chain requires asking precise questions — not accepting polished documentation at face value.

Most researchers encounter a Certificate of Analysis (COA) and treat it as the final word on a compound's origin. It is not. A COA confirms what a testing laboratory detected in a finished sample. It does not confirm where the active pharmaceutical ingredient was chemically synthesized. That distinction is the core of this audit framework.

Step 1: Request the country of origin for raw materials — separately from the COA.

Ask the vendor directly: "Where was the peptide or active ingredient synthesized?" A domestic bottling address and a COA from a US-based testing lab tell you nothing about raw material origin. Require a written response that names the synthesis country, not just the finished product's packaging location.

Step 2: Interpret the COA carefully — distinguish "Manufacturer" from "Distributor."

A COA lists the entity that submitted the sample for testing. That entity is frequently a domestic distributor, not the original manufacturer. If the COA names a US company as "Manufacturer" but no synthesis documentation exists, the label reflects commercial ownership, not production geography. Cross-reference the COA against a supplier data sheet or a raw material specification that names the actual synthesis facility.

Step 3: Ask vendor support these specific questions before purchasing.

Use this template as a baseline for any experimental compound inquiry:

  • "Where was the active ingredient chemically synthesized — which country and facility?"
  • "Can you provide a supplier data sheet or raw material specification naming the synthesis site?"
  • "Is your 'Made in USA' claim unqualified, or does it refer only to finishing and packaging?"
  • "Do you hold documentation from your raw material supplier confirming domestic origin?"

Written responses matter here. Vague or deflective answers are themselves informative.

Step 4: Reference the FTC's 16 CFR Part 323 as a leverage tool.

The FTC's Made in USA Labeling Rule carries civil penalties of up to $43,280 per violation. Citing this rule in correspondence signals to vendors that the inquiry is informed and serious. The FTC's compliance standard requires that "all or virtually all" of a product's content originate domestically — a bar most supplement brands quietly fail.

The next section consolidates these audit steps into key takeaways every researcher should carry before evaluating any origin claim.

The bottom line: Key takeaways for researchers

Understanding what "Made in USA" actually requires — versus what most supplement labels actually deliver — is the foundation of evidence-aware compound sourcing.

Previous sections covered how marketing language obscures supply chain reality and how to audit vendor documentation. These takeaways distill that analysis into a structured reference for researchers evaluating experimental compounds.

  • Unqualified "Made in USA" is a high legal bar. Per the FTC's Made in USA standard, an unqualified claim requires that "all or virtually all" of the product — including raw materials and processing — originate domestically. Few experimental peptides or longevity compounds clear this threshold without qualification.

  • Most supplements are US-packaged, not US-manufactured. The dominant supply chain model routes bulk raw materials — frequently synthesized overseas — to domestic facilities for encapsulation, bottling, and labeling. The final product carries a US address. The active compound does not. Per FTC enforcement policy, qualified claims must clearly state the extent of foreign processing to avoid being deceptive.

  • GMP certification is facility-level, not ingredient-level. A GMP-certified facility validates that manufacturing processes meet quality and consistency standards inside that building. It says nothing about where the precursor chemicals or synthesized peptides originated. Researchers who conflate facility certification with ingredient origin are misreading what the certification actually covers.

  • Transparency requires tracing the synthesis location. Bottling site and country of registration are insufficient data points. The critical variable is where the chemical synthesis occurred — which raw API supplier provided the compound, and what documentation verifies its identity and purity. Without a verifiable chain of custody reaching back to the synthesis step, "Made in USA" functions as a bottling address, not a quality guarantee.

The practical implication: Researchers should build sourcing decisions around compound verification — COAs from accredited third-party labs, confirmed API origin documentation, and synthesis-level traceability — rather than label language designed for consumer confidence rather than research accuracy.

These distinctions matter because the evidence quality of any experimental compound depends partly on the integrity of the compound itself. A mislabeled or substituted material cannot generate reliable mechanistic data — regardless of what the label claims.

What emerges from this analysis is a clear need for a framework that goes beyond label auditing — one that centers mechanism analysis and vendor transparency as equal priorities. That is precisely where a structured research perspective adds value.

HackedAlive's perspective: Beyond the label

A "Made in USA" label tells you where a product was finished — not whether the underlying science supports its use. That distinction is the foundation of everything HackedAlive builds toward.

The peptide and experimental compound space rewards confident marketing language. Labels invoke domestic manufacturing, GMP certification, and third-party testing as proxies for quality and efficacy. But as the previous sections of this guide make clear, each of those signals requires active interpretation — not passive acceptance. The FTC's own compliance framework sets a legal threshold for origin claims, yet it says nothing about whether a compound's mechanism translates from animal data to meaningful human outcomes.

HackedAlive's approach centers on mechanism analysis precisely because marketing claims and biological plausibility are two separate conversations. Understanding how a compound interacts with mitochondrial function, cellular signaling, or bioenergetics pathways requires a different lens than evaluating a Certificate of Analysis or confirming a domestic manufacturing address. Both conversations matter — but conflating them is how researchers end up with well-labeled products that lack credible human evidence.

Vendor Transparency Reports serve a specific function within that framework. They are not product endorsements. They are structured evaluations of sourcing documentation, synthesis disclosures, and dose-response relationship data — designed to help readers move from surface-level label reading to substantive compound verification. The goal is research literacy, not purchasing guidance.

The broader shift HackedAlive advocates for is a verification-first culture — one where researchers ask supply chain questions before committing to a compound, treat Certificate of Analysis documents as starting points rather than endpoints, and hold the gap between mechanistic theory and human evidence clearly in view. That culture does not develop from better labels. It develops from better frameworks.

The transparency gap described here is real, persistent, and unlikely to close through regulatory action alone. Closing it requires researchers who understand what questions to ask and why the answers matter.

For readers who want to continue building that foundation:

IN THIS ARTICLE

← TOC